NanoVibronix Inc (NASDAQ: NAOV) is screaming for the top in the market this morning, and for good reason. The company released positive findings from a third-party evaluation of its UroShield device. Here’s what’s going on:
Attention Alpha Stock News Readers: You now have FREE access to Joshua Rodriguez’s investing portfolio. Click here.
NAOV Stock Rockets On Third Party Device Evaluation
In the press release, NanoVibronix announced findings from an independent evaluation of UroShield on patients who have used the device for up to two years. The company said that the results have been submitted to the National Institute for Health and Care Excellence for review and consideration.
NAOV went on to explain that the independent statistical analysis was conducted by Coventry University’s Assistant Professor, Ksenija Maravic da Silva. The analysis resulted in statistically significant outcomes for the patients using the UroShield device.
Importantly, the findings demonstrated a reduced number of UTIs, reduced instances of prescribed antibiotics, reduce catheter blockages, reduced need for unplanned catheter changes, and reduced pain. Moreover, the study also provided insights into the well-being of patients using the product.
In a statement, Brian Murphy, CEO at NAOV, had the following to offer:
Findings from an independent study demonstrate significant benefits of our UroShield device with patients reporting reductions in blockages, catheter changes and use of bladder maintenance solutions in addition to reductions in pain, fewer visits to clinics and hospitals for emergency catheter changes. As part of our ongoing engagement, we submitted these findings to NICE as part of the process for attaining ‘official guidance’ from the organization, an important step in providing access to all NHS patients at risk of catheter associated urinary tract infections. We believe that these findings should also reinforce our efforts in the U.S. and other target markets.
Tangentially, patients also reported an overall improvement in their mental state, which was described as ‘priceless’ and ‘life changing’ by study participants and their loved ones. Beyond the physical health benefits, patients cited improved sleep, higher levels of energy, increased confidence and desire to socialize with family and friends. We remain committed to full commercialization of our products, and the real-world findings and testimonials from this study further substantiate what we already know to be true about the efficacy of UroShield.
Seriously, Joshua shares his investing portfolio with Alpha Stock News readers here.
This Is Big News
The news released by NanoVibronix this morning proved to be overwhelmingly positive. After all, the company’s own data is biased. When a third party releases such positive results, it shows that the product is a good one.
That’s exactly the case here. Patients using UroShield saw a tremendous reduction in symptoms and improvement in quality of life. What more could you ask for. All in all, that’s great news for NAOV stock and its investors.
Don’t Miss The Next Big Story
Join our free mailing list below to receive real-time news alerts and gain access to Joshua’s investing portfolio!
Click here to subscribe if reading on mobile.
Top Trading Services
|Service||Trade Ideas||eToro||Investors Underground|
|Key Features||– AI-Based Trade Ideas|
– Simulated Trading
– Alert Windows
– Quality Charting Tools
– One Click Trading
|– Automated Trading|
– Copy successful Traders
– Get Copied Get Paid
– $0 Commissions
– Educational Resources
|– Premarket Broadcast|
– Live Trading Floor
– Nightly Watch List
– Morning Call
– 1,000+ Video Lessons
|Rating||4.7 out of 5||4.5 out of 5||4.2 out of 5|
|Price||$118 – $228 per month|
$1,068 – $2,268 per year
|FREE||$297 per month,|
$697 per quarter, or
$1,897 per year
|Sign Up||Sign Up Now!||Sign Up Now!||Sign Up Now!|